End-of-day quote
Other stock markets
|
||
- USD | - |
Jul. 02 | Innoviva, Inc.'s Subsidiary Innoviva Specialty Therapeutics, Inc. Appoints Patricia Drake as Chief Commercial Officer | CI |
Jun. 18 | Cantor Fitzgerald Initiates Innoviva at Overweight Rating | MT |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Respiratory Products
100.0
%
| 331 | 100.0 % | 310 | 100.0 % | -6.30% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 331 | 100.0 % | 310 | 100.0 % | -6.30% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Pavel Raifeld
CEO | Chief Executive Officer | 40 | 20-05-19 |
Stephen Basso
DFI | Director of Finance/CFO | 58 | 23-08-20 |
Marianne Zhen
AUD | Comptroller/Controller/Auditor | 55 | 14-09-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 64 | 18-02-11 | |
Director/Board Member | 53 | 22-12-31 | |
Jules Haimovitz
BRD | Director/Board Member | 73 | 18-02-11 |
Odysseas Kostas
BRD | Director/Board Member | 49 | 17-12-18 |
Mark Dipaolo
CHM | Chairman | 53 | 18-02-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 94,449,778 | 61,857,437 ( 65.49 %) | 32,005,000 ( 33.89 %) | 65.49 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
ARMATA PHARMACEUTICALS, INC. 69.36% | 25,076,769 | 69.36% | 68,961,115 $ |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+62.66% | 841B | |
+40.42% | 625B | |
-4.37% | 360B | |
+17.16% | 327B | |
+9.87% | 300B | |
+15.66% | 242B | |
+17.90% | 227B | |
+14.86% | 174B | |
+0.45% | 162B |
- Stock Market
- Equities
- INVA Stock
- Stock
- Company Theravance Inc